In comparison with the adjacent normal tissues, ACBD3 expression was statistically upregulated in thirteen cancers, including STAD, prostate adenocarcinoma (PRAD), pancreatic adenocarcinoma (PAAD), LUSC, LUAD, LIHC, kidney renal papillary cell carcinoma (KIRP), KIRC, HNSC, ESCA, CHOL, BRCA, and bladder urothelial carcinoma (BLCA), and downregulated in KICH and THCA (Fig. 1B). Here, ACBD3 is linked to prostate adenocarcinoma.